Acrux investors have taken heart from a ruling by the European drug regulator that testosterone therapy does not increase the risk of cardiac problems.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Acrux investors have taken heart from a ruling by the European drug regulator that testosterone therapy does not increase the risk of cardiac problems.
The biotechnology stock surged 24 per cent to $1.28 on Friday after the European Medicines Agency memo.
Fetching latest articles
Original URL: https://www.afr.com/companies/healthcare-and-fitness/acrux-gets-good-news-in-europe-20141125-11t20d
